think these vaccine should be available, very close to the marginal cost is something we help gavi kenichi related to that is would like to avoid overpayments for the vaccine's. there's a lot of contributions companies are making, also love contribution that governments are making to help pay for these vaccines. we certainly support direct compensation for the investment companies are making. in so far as we can ensure the vaccines are failed of its marginal cost. we should also member there are other incentives have been introduced the potential report companies were development of these vaccines including -- a very important sum of money to encourage companies to the vaccines or drugs against specific diseases. congress has just admitted legislation to include ebola. these are all very important but we need to make sure in terms of how this funding is being provided to make sure it is well coordinated as we've been discussing. the last issue about equitable distribution. we are moving towards industrial scale production to a lot of these vaccine put in the short and medium term there'll